S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:KPTI

Karyopharm Therapeutics (KPTI) Stock Forecast, Price & News

$2.21
-0.13 (-5.56%)
(As of 06/9/2023 ET)
Compare
Today's Range
$2.20
▼
$2.35
50-Day Range
$2.20
▼
$4.59
52-Week Range
$2.15
▼
$6.03
Volume
1.21 million shs
Average Volume
2.61 million shs
Market Capitalization
$251.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Karyopharm Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
262.0% Upside
$8.00 Price Target
Short Interest
Bearish
15.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.56mentions of Karyopharm Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$54,048 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.24) to ($1.02) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

286th out of 987 stocks

Pharmaceutical Preparations Industry

127th out of 477 stocks

See Top Rated MarketRank™ Stocks Here

KPTI stock logo

About Karyopharm Therapeutics (NASDAQ:KPTI) Stock

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Stock News Headlines

June 8, 2023 | finance.yahoo.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is favoured by institutional owners who hold 74% of the company
June 7, 2023 | markets.businessinsider.com
SVB Securities Sticks to Their Hold Rating for Karyopharm Therapeutics (KPTI)
June 9, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
June 6, 2023 | americanbankingnews.com
Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Target Price at $8.00
May 29, 2023 | markets.businessinsider.com
SVB Securities Remains a Hold on Karyopharm Therapeutics (KPTI)
May 23, 2023 | finance.yahoo.com
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
May 18, 2023 | msn.com
Karyopharm Therapeutics's Return On Capital Employed Insights
May 12, 2023 | americanbankingnews.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of "Moderate Buy" by Brokerages
June 9, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
May 9, 2023 | finance.yahoo.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2023 Earnings Call Transcript
May 9, 2023 | americanbankingnews.com
Wedbush Weighs in on Karyopharm Therapeutics Inc.'s FY2027 Earnings (NASDAQ:KPTI)
May 7, 2023 | americanbankingnews.com
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Cut to $10.00 by Analysts at Robert W. Baird
May 6, 2023 | msn.com
Baird Maintains Karyopharm Therapeutics (KPTI) Outperform Recommendation
May 5, 2023 | finanznachrichten.de
Karyopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 5, 2023 | msn.com
HC Wainwright & Co. Maintains Karyopharm Therapeutics (KPTI) Buy Recommendation
May 5, 2023 | msn.com
RBC Capital Maintains Karyopharm Therapeutics (KPTI) Outperform Recommendation
May 5, 2023 | finance.yahoo.com
Karyopharm Therapeutics First Quarter 2023 Earnings: Beats Expectations
May 5, 2023 | americanbankingnews.com
HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $10.00
May 4, 2023 | finance.yahoo.com
Why Karyopharm Therapeutics Shares Slumped Thursday
May 4, 2023 | msn.com
Karyopharm hits four-month low after guidance cut
May 4, 2023 | finance.yahoo.com
Karyopharm Therapeutics (KPTI) Q1 2023 Earnings Call Transcript
May 4, 2023 | finance.yahoo.com
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 3, 2023 | finance.yahoo.com
Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS
April 27, 2023 | finance.yahoo.com
Will Karyopharm Therapeutics (KPTI) Report Negative Q1 Earnings? What You Should Know
April 26, 2023 | americanbankingnews.com
Reshma Rangwala Sells 6,770 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock
April 23, 2023 | americanbankingnews.com
Karyopharm Therapeutics (NASDAQ:KPTI) Given "Buy" Rating at HC Wainwright
April 23, 2023 | americanbankingnews.com
Brokers Offer Predictions for Karyopharm Therapeutics Inc.'s FY2023 Earnings (NASDAQ:KPTI)
See More Headlines

KPTI Price History

KPTI Company Calendar

Last Earnings
11/03/2021
Today
6/09/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KPTI
CUSIP
N/A
CIK
1503802
Web
www.karyopharm.com
Phone
(617) 658-0600
Fax
N/A
Employees
442
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+241.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-165,290,000.00
Net Margins
-106.69%
Pretax Margin
-106.50%
Return on Equity
N/A
Return on Assets
-53.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.17
Quick Ratio
5.11

Sales & Book Value

Annual Sales
$157.07 million
Price / Sales
1.70
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.15) per share
Price / Book
-15.60

Miscellaneous

Outstanding Shares
114,010,000
Free Float
110,225,000
Market Cap
$266.78 million
Optionable
Optionable
Beta
0.05

Key Executives

  • Richard A. Paulson
    President, CEO & Non-Executive Director
  • Sharon ShachamSharon Shacham
    Scientific Advisory Board
  • Mike Mason
    Chief Financial Officer, Treasurer & EVP
  • Reshma Rangwala
    Chief Medical Officer
  • Amama Sadiq
    Senior VP-Global Medical & Scientific Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KPTI Stock - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPTI shares.
View KPTI analyst ratings or view top-rated stocks.

What is Karyopharm Therapeutics' stock price forecast for 2023?

7 brokerages have issued 1-year price targets for Karyopharm Therapeutics' stock. Their KPTI share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 241.9% from the stock's current price.
View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts.

How have KPTI shares performed in 2023?

Karyopharm Therapeutics' stock was trading at $3.40 at the beginning of the year. Since then, KPTI stock has decreased by 31.2% and is now trading at $2.34.
View the best growth stocks for 2023 here.

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our KPTI earnings forecast.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) released its earnings results on Wednesday, November, 3rd. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by $0.01. The business earned $37.69 million during the quarter, compared to analyst estimates of $25.84 million. During the same quarter in the previous year, the business earned ($0.73) EPS.

What ETFs hold Karyopharm Therapeutics' stock?

ETFs with the largest weight of Karyopharm Therapeutics (NASDAQ:KPTI) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares Genomics Immunology and Healthcare ETF (IDNA), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Invesco Nasdaq Biotechnology ETF (IBBQ).

What guidance has Karyopharm Therapeutics issued on next quarter's earnings?

Karyopharm Therapeutics issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $145.00 million-$160.00 million, compared to the consensus revenue estimate of $157.37 million.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (8.93%), BlackRock Inc. (7.96%), Palo Alto Investors LP (4.98%), Rubric Capital Management LP (3.90%), Barclays PLC (2.50%) and Bank of America Corp DE (1.89%). Insiders that own company stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener, Stuart Poulton and Tanya Lewis.
View institutional ownership trends.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $2.34.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $266.78 million and generates $157.07 million in revenue each year. The company earns $-165,290,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

The company employs 442 workers across the globe.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com.

This page (NASDAQ:KPTI) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -